Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (Q30315977)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

phase II clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Carsten Müller-Tidow

5

object named as

Carsten Müller-Tidow

0 references

Gerhard Ehninger

44

object named as

Gerhard Ehninger

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Martin Bornhäuser

35

object named as

Martin Bornhäuser

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Aristoteles A N Giagounidis

15

object named as

Aristoteles Giagounidis

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Hermann Einsele

10

object named as

Hermann Einsele

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Christian Thiede

39

object named as

Christian Thiede

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Johannes Schetelig

41

object named as

Johannes Schetelig

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Stefan W. Krause

1 reference

ORCID Public Data File 2021

Malte von Bonin

40

object named as

Malte von Bonin

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Christoph Röllig

1

object named as

Christoph Röllig

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Christian H Brandts

8

object named as

Christian H Brandts

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Kerstin Schäfer-Eckart

12

object named as

Kerstin Schäfer-Eckart

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Claudia D Baldus

7

object named as

Claudia D Baldus

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

20

object named as

Mathias Hänel

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

11

object named as

Alwin Krämer

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Walter E Aulitzky

18

object named as

Walter Aulitzky

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

6

object named as

Utz Krug

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

36

object named as

Markus Schaich

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

2

object named as

Hubert Serve

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Alexander Kiani

21

object named as

Alexander Kiani

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

34

object named as

Thomas Illmer

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Stefani Parmentier

37

object named as

Stefani Parmentier

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Volker Kunzmann

9

object named as

Volker Kunzmann

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Andreas Burchert

14

object named as

Andreas Burchert

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Norbert Frickhofen

22

object named as

Norbert Frickhofen

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Richard Noppeney

4

object named as

Richard Noppeney

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

30

object named as

Frank Heits

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Johannes Kullmer

23

object named as

Johannes Kullmer

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

29

object named as

Roland Repp

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

33

object named as

Ina-Maria Klut

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Wolfgang E Berdel

43

object named as

Wolfgang E Berdel

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

author name string

Andreas Hüttmann

3

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Andreas Neubauer

13

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Stefan W Krause

16

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Andreas Mackensen

17

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Regina Herbst

19

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Ulrich Kaiser

24

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Hartmut Link

25

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Thomas Geer

26

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Albert Reichle

27

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Christian Junghanß

28

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Heinz Dürk

31

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Jana Hase

32

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Martin Görner

38

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Michael Kramer

42

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Study Alliance Leukaemia

45

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

publication date

5 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

1691-1699

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900362-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00362-9

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30315977&oldid=2138404193"